The ASCO Insurance Coverage of Clinical Trials Toolkit is available to assist research sites with issues related to insurance coverage for patients participating in clinical trials. Developed by the ASCO Research Community Forum (RCF), the free toolkit contains sample checklists, templates, and forms to help sites determine insurance coverage for clinical trials, deal with coverage denials, and navigate the appeals process.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
In a new ASCO in Action Podcast, ASCO Vice President of Clinical Affairs Stephen Grubbs, MD, FASCO, joins ASCO CEO Dr. Clifford A. Hudis, FACP, FASCO, to break down the Quality Payment Program (QPP) and discuss the reimbursement changes coming to oncology practices in the United States.
On June 22, ASCO and the Food and Drug Administration will co-host an event, the Core Outcome Assessments in Cancer Clinical Trials workshop.
On March 22-23, the National Cancer Institute (NCI) will host a free meeting on Cancer, Autoimmunity, and Immunology.
ASCO's new social media tolkit helps members raise awareness of the National Cancer Institute's important role in advancing cancer research.
In a new ASCO in Action podcast, ASCO President Bruce E. Johnson, MD, FASCO, joined ASCO Chief Executive Officer Dr. Clifford A. Hudis to discuss precision medicine—Dr. Johnson’s presidential theme and the focus of ASCO’s recent State of Cancer Care in America event at the National Press Club.
ASCO submitted comments to the Centers for Medicare & Medicaid Services on proposed changes to Medicare Advantage and Medicare Part D prescription plans for 2019. The comments included recommendations for updating prior authorization requirements as well as feedback on policies to address the national opioid epidemic.
ASCO’s new checklist, “Evaluating Oncology Clinical Pathways Programs,” is designed to guide oncology practices in examining the pathway programs they currently use, or to evaluate pathways under consideration for future use.
ASCO is launching ASCO Practice Central, a new website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. The first ASCO website dedicated to the business of oncology, ASCO Practice Central provides a one-stop, centralized resource that oncology practices can use to address a wide range of practical issues, including changes to physician reimbursement, quality reporting requirements, and business management practices.
March 4, 2018, is International HPV Awareness Day, which aims to promote education about human papillomavirus (HPV), raise awareness about prevention methods, and encourage governments and individuals to take advantage of the HPV vaccine and screening for cancer.
On February 26, 2018, the Food and Drug Administration approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
ASCO submitted comments to the Senate Finance Committee on addressing the opioid epidemic in the United States. ASCO is concerned about the epidemic and its devastating impact on too many Americans and wants to ensure that any efforts to address the epidemic do not inadvertently limit access to appropriate medical therapy for patients with cancer.
On February 16, 2018, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
The American Medical Association (AMA) recently launched the “Share Your Story” campaign as part of its work to end the opioid epidemic in the United States. ASCO is now accepting campaign submissions from the oncology community highlighting physician efforts to provide appropriate care in the midst of the epidemic and to urge payers and policymakers to improve access to treatment.
Eligible clinicians who submitted 2017 Quality performance data for the Merit-Based Incentive Payment System (MIPS) via claims can view performance scores through the MIPS data submission feature on the Quality Payment Program (QPP) website. Note: claims data submission is only an option if you’re participating in MIPS as an individual, not as part of a group.